The IL1R1 Knockout NCI-H1299 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal human cell population in which the IL1R1 gene has been functionally disrupted. This polyclonal knockout product is generated from the NCI-H1299 non-small cell lung carcinoma cell line and provides a heterogeneous loss-of-function model for studies of interleukin-1 receptor type I signaling. As a polyclonal population, the cells reflect a spectrum of editing events, enabling robust assessment of IL1R1-dependent phenotypes without the constraints of monoclonal selection. The knockout model serves as a versatile tool for dissecting the contributions of IL1R1 to pro-inflammatory and oncogenic signaling networks.
The host cell line, NCI-H1299, is a widely employed human non-small cell lung carcinoma (NSCLC) model derived from a lymph node metastasis of a lung adenocarcinoma. These epithelial cells harbor characteristic genetic alterations associated with NSCLC and are extensively utilized to investigate lung cancer biology, including tumor progression, metastasis, and therapeutic responses. The NCI-H1299 background provides a clinically relevant context for examining the role of IL-1 signaling in a tumor type where inflammatory pathways are increasingly recognized as drivers of malignancy and immune evasion.
IL1R1 encodes the primary receptor for the pleiotropic cytokines interleukin-1 alpha (IL1A) and interleukin-1 beta (IL1B). Ligand engagement triggers heterodimerization with the accessory protein IL1RAP and recruitment of the adaptor MyD88, leading to activation of interleukin-1 receptor-associated kinases IRAK1 and IRAK4. These kinases in turn activate the E3 ubiquitin ligase TRAF6 and the kinase TAK1, which propagate signals through the I??B kinase (IKK) complex to release NF-??B transcription factors, notably RELA and NFKB1. Concurrently, TAK1 stimulates MAP kinase cascades, including p38, JNK, and ERK, culminating in the activation of AP-1 components such as JUN and FOS. This signaling network drives transcriptional induction of numerous pro-inflammatory mediators, including IL6, CXCL8, PTGS2, and matrix metalloproteinases (MMPs). The system is modulated by upstream regulators like the endogenous antagonist IL1RN, as well as TNF and LPS, which can prime or synergize with IL-1 responses.
In the NCI-H1299 NSCLC context, IL1R1 signaling is implicated in shaping an inflammatory tumor microenvironment that facilitates proliferation, survival, and chemoresistance. Autocrine or paracrine IL-1 may activate NF-??B and MAPK cascades to enhance expression of cytokines, angiogenic factors, and invasion-promoting proteases. By ablating IL1R1 function, this polyclonal knockout model allows researchers to interrogate how the receptor contributes to aggressive lung adenocarcinoma phenotypes, including cross-talk between cancer cells and infiltrating immune cells. The model is particularly valuable for evaluating the dependence of downstream effectors such as RELA, JUN, IL6, and CXCL8 on intact IL-1 signaling, and for testing the ability of the tumor cells to bypass receptor loss via alternative pathways.
This knockout product supports a wide range of experimental applications, including quantitative analysis of IL-1?Cstimulated signaling via western blotting for phospho-p65 and phospho-JNK, RT-qPCR profiling of IL1R1 transcript loss and cytokine induction, and NF-??B luciferase reporter assays to measure transcriptional activity. Functional readouts such as proliferation, viability, migration, and invasion assays can be paired with cytokine multiplex ELISAs or RNA sequencing to map global expression changes. The cells are also suitable for investigating the impact of IL1R1 disruption on response to chemotherapeutics or targeted agents, and for high-throughput screening of anti-inflammatory compounds that might circumvent IL-1?Cdriven tumor progression. For further details and ordering information, please contact Ascent Research.
